Cargando…
Ib-M6 Antimicrobial Peptide: Antibacterial Activity against Clinical Isolates of Escherichia coli and Molecular Docking
The Ib-M6 peptide has antibacterial activity against non-pathogenic Escherichia coli K-12 strain. The first part of this study determines the antibacterial activity of Ib-M6 against fourteen pathogenic strains of E. coli O157:H7. Susceptibility assay showed that Ib-M6 had values of Minimum Inhibitor...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7168133/ https://www.ncbi.nlm.nih.gov/pubmed/32059550 http://dx.doi.org/10.3390/antibiotics9020079 |
_version_ | 1783523617524416512 |
---|---|
author | Flórez-Castillo, J. M. Rondón-Villareal, P. Ropero-Vega, J. L. Mendoza-Espinel, S. Y. Moreno-Amézquita, J. A. Méndez-Jaimes, K. D. Farfán-García, A. E. Gómez-Rangel, S. Y. Gómez-Duarte, Oscar Gilberto |
author_facet | Flórez-Castillo, J. M. Rondón-Villareal, P. Ropero-Vega, J. L. Mendoza-Espinel, S. Y. Moreno-Amézquita, J. A. Méndez-Jaimes, K. D. Farfán-García, A. E. Gómez-Rangel, S. Y. Gómez-Duarte, Oscar Gilberto |
author_sort | Flórez-Castillo, J. M. |
collection | PubMed |
description | The Ib-M6 peptide has antibacterial activity against non-pathogenic Escherichia coli K-12 strain. The first part of this study determines the antibacterial activity of Ib-M6 against fourteen pathogenic strains of E. coli O157:H7. Susceptibility assay showed that Ib-M6 had values of Minimum Inhibitory Concentration (MIC) lower than streptomycin, used as a reference antibiotic. Moreover, to predict the possible interaction between Ib-M6 and outer membrane components of E. coli, we used molecular docking simulations where FhuA protein and its complex with Lipopolysaccharide (LPS–FhuA) were used as targets of the peptide. FhuA/Ib-M6 complexes had energy values between −39.5 and −40.5 Rosetta Energy Units (REU) and only one hydrogen bond. In contrast, complexes between LPS–FhuA and Ib-M6 displayed energy values between −25.6 and −40.6 REU, and the presence of five possible hydrogen bonds. Hence, the antimicrobial activity of Ib-M6 peptide shown in the experimental assays could be caused by its interaction with the outer membrane of E. coli. |
format | Online Article Text |
id | pubmed-7168133 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-71681332020-04-21 Ib-M6 Antimicrobial Peptide: Antibacterial Activity against Clinical Isolates of Escherichia coli and Molecular Docking Flórez-Castillo, J. M. Rondón-Villareal, P. Ropero-Vega, J. L. Mendoza-Espinel, S. Y. Moreno-Amézquita, J. A. Méndez-Jaimes, K. D. Farfán-García, A. E. Gómez-Rangel, S. Y. Gómez-Duarte, Oscar Gilberto Antibiotics (Basel) Article The Ib-M6 peptide has antibacterial activity against non-pathogenic Escherichia coli K-12 strain. The first part of this study determines the antibacterial activity of Ib-M6 against fourteen pathogenic strains of E. coli O157:H7. Susceptibility assay showed that Ib-M6 had values of Minimum Inhibitory Concentration (MIC) lower than streptomycin, used as a reference antibiotic. Moreover, to predict the possible interaction between Ib-M6 and outer membrane components of E. coli, we used molecular docking simulations where FhuA protein and its complex with Lipopolysaccharide (LPS–FhuA) were used as targets of the peptide. FhuA/Ib-M6 complexes had energy values between −39.5 and −40.5 Rosetta Energy Units (REU) and only one hydrogen bond. In contrast, complexes between LPS–FhuA and Ib-M6 displayed energy values between −25.6 and −40.6 REU, and the presence of five possible hydrogen bonds. Hence, the antimicrobial activity of Ib-M6 peptide shown in the experimental assays could be caused by its interaction with the outer membrane of E. coli. MDPI 2020-02-12 /pmc/articles/PMC7168133/ /pubmed/32059550 http://dx.doi.org/10.3390/antibiotics9020079 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Flórez-Castillo, J. M. Rondón-Villareal, P. Ropero-Vega, J. L. Mendoza-Espinel, S. Y. Moreno-Amézquita, J. A. Méndez-Jaimes, K. D. Farfán-García, A. E. Gómez-Rangel, S. Y. Gómez-Duarte, Oscar Gilberto Ib-M6 Antimicrobial Peptide: Antibacterial Activity against Clinical Isolates of Escherichia coli and Molecular Docking |
title | Ib-M6 Antimicrobial Peptide: Antibacterial Activity against Clinical Isolates of Escherichia coli and Molecular Docking |
title_full | Ib-M6 Antimicrobial Peptide: Antibacterial Activity against Clinical Isolates of Escherichia coli and Molecular Docking |
title_fullStr | Ib-M6 Antimicrobial Peptide: Antibacterial Activity against Clinical Isolates of Escherichia coli and Molecular Docking |
title_full_unstemmed | Ib-M6 Antimicrobial Peptide: Antibacterial Activity against Clinical Isolates of Escherichia coli and Molecular Docking |
title_short | Ib-M6 Antimicrobial Peptide: Antibacterial Activity against Clinical Isolates of Escherichia coli and Molecular Docking |
title_sort | ib-m6 antimicrobial peptide: antibacterial activity against clinical isolates of escherichia coli and molecular docking |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7168133/ https://www.ncbi.nlm.nih.gov/pubmed/32059550 http://dx.doi.org/10.3390/antibiotics9020079 |
work_keys_str_mv | AT florezcastillojm ibm6antimicrobialpeptideantibacterialactivityagainstclinicalisolatesofescherichiacoliandmoleculardocking AT rondonvillarealp ibm6antimicrobialpeptideantibacterialactivityagainstclinicalisolatesofescherichiacoliandmoleculardocking AT roperovegajl ibm6antimicrobialpeptideantibacterialactivityagainstclinicalisolatesofescherichiacoliandmoleculardocking AT mendozaespinelsy ibm6antimicrobialpeptideantibacterialactivityagainstclinicalisolatesofescherichiacoliandmoleculardocking AT morenoamezquitaja ibm6antimicrobialpeptideantibacterialactivityagainstclinicalisolatesofescherichiacoliandmoleculardocking AT mendezjaimeskd ibm6antimicrobialpeptideantibacterialactivityagainstclinicalisolatesofescherichiacoliandmoleculardocking AT farfangarciaae ibm6antimicrobialpeptideantibacterialactivityagainstclinicalisolatesofescherichiacoliandmoleculardocking AT gomezrangelsy ibm6antimicrobialpeptideantibacterialactivityagainstclinicalisolatesofescherichiacoliandmoleculardocking AT gomezduarteoscargilberto ibm6antimicrobialpeptideantibacterialactivityagainstclinicalisolatesofescherichiacoliandmoleculardocking |